… types of recommended treatments: bronchodilator therapy, combined long-acting beta-2-…
a negative predictor in COPD [Citation26], while overweight could be a marker for more stable …

… of exacerbation history as a predictor of future exacerbation risk [… patients with dyspnoea on
two long-acting bronchodilators, … at this point, these patients should have already undergone …

… The working group identifies long-acting bronchodilators as the main preventive therapy for
exacerbations in patients with no criteria for ACO. It is clear that the effect of this treatment on …

… safety of long-acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA)
in … stable COPD, with the only recommendation being the use of long-acting bronchodilator …

… β 2 -agonist (LAMA/LABA) dual therapy, a combination of two bronchodilator … COPD codes
in CPRD medical records could identify patients with COPD with a high positive predictive …

… Each patient underwent the bronchodilation test irrespective … any inhaled corticosteroid
(ICS)/long-acting β 2 -agonists (LABA… low phenotypes for predicting treatment responsiveness in …

… COPD patients with FEV 1 50% to 80% of predicted value and not for severe COPD patients
(FEV 1 30% to 50% of predicted … , in addition to treatment with long-acting bronchodilators. …

… a cohort of 3,500 patients with stable COPD in Central and … of dual long-acting bronchodilation
in improving key COPD-… predictor of a beneficial response to ICS treatment in COPD, as …

… treatment with oral corticosteroids. A total of 632 of these individuals were on long-acting
bronchodilators with … and identified as on maintenance treatment, whereas the remaining 2543 …

… safety of long-acting β2-agonist (LABA)/long-acting muscarinic … Long-acting bronchodilator
combinations (LAMA/LABA FDCs… can predict efficacy characteristics during long-term drug …